Author:
Lu Mei,Rupp Loralee B.,Melkonian Christina,Trudeau Sheri,Daida Yihe G.,Schmidt Mark A.,Gordon Stuart C.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference14 articles.
1. Lampertico P, Carrion JA, Curry M, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis. J Hepatol. 2020;72(6):1112–21.
2. US Food and Drug Administration. Mavret Summary Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209394Orig1s000SumR.pdf. Accessed 1 May 2023.
3. US Food and Drug Administration. Mavret: Label for New Patient Population. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209394s006lbl.pdf. Accessed May 1, 2023.
4. Brown RS Jr, Buti M, Rodrigues L, et al. Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1–6 and compensated cirrhosis: the EXPEDITION-8 trial. J Hepatol. 2020;72(3):441–9.
5. US Food and Drug Administration. Mavyret Labeling Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209394s010lbl.pdf. Published 2020. Accessed 2023.